Brief: Context Therapeutics Submits IND Application To Evaluate CTIM-76 In Claudin 6-Positive Cancers
01/04/2024 12:52
April 1 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS SUBMITS IND APPLICATION TO EVALUATE
CTIM-76
IN CLAUDIN 6-POSITIVE CANCERS
Source text for Eikon: ID:nGNX6vYDDH
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202